Results 51 to 60 of about 22,482 (226)

Plain language summary of publication of the 48-week results from the PHOTON study: intravitreal aflibercept 8 mg for diabetic macular edema

Therapeutic Advances in Ophthalmology
Summary What is this summary about? This is a summary of a publication about the PHOTON study, which was published in The Lancet . Diabetic macular edema (DME) is a serious and common complication of diabetes, with an estimated global prevalence of 5.5 ...
David M. Brown, David S. Boyer, Diana V. Do, Charles C. Wykoff, Taiji Sakamoto, Peter Win, Sunir Joshi, Hani Salehi-Had, András Seres, Alyson J. Berliner, Sergio Leal, Robert Vitti, Karen W. Chu, Kimberly Reed, Rohini Rao, Yenchieh Cheng, Delia Voronca, Rafia Bhore, Ursula Schmidt-Ott, Thomas Schmelter, Andrea Schulze, Xin Zhang, Sobha Sivaprasad   +22 more
doaj   +1 more source

Effect of Faricimab versus Aflibercept on Hyperreflective Foci in Patients with Diabetic Macular Edema from the YOSEMITE/RHINE Trials

Ophthalmology Science
Purpose To compare the effect of faricimab, a dual angiopoietin-2 (Ang-2) and VEGF-A inhibitor, with aflibercept on resolution of hyperreflective foci (HRF) in patients with diabetic macular edema (DME).
U. Chakravarthy, Varun Chaudhary, S. Sadda, Colin S. Tan, S. Vujosevic, Sascha Fauser, K. Gibson, Carl Glittenberg, Nancy M Holekamp, B. Lanza, Andreas Maunz, Jeffrey R. Willis, Rishi P. Singh   +12 more
semanticscholar   +1 more source

Adult‐onset Coats disease: A systematic review and meta‐analysis of imaging biomarkers and targeted therapies

Acta Ophthalmologica, EarlyView.
Abstract Coats disease diagnosed in adulthood is a rare idiopathic retinal telangiectatic vasculopathy that may differ in phenotype from childhood‐diagnosed cases. This systematic review synthesizes current evidence to characterize its clinical spectrum, imaging features, treatment outcomes and underlying mechanisms, with a focus on immunovascular ...
Catarina Francisco, Nisa Silva, Camiel J. F. Boon   +2 more
wiley   +1 more source

Effect of intravitreal aflibercept injection for age-related macular degeneration with a retinal pigment epithelial tear refractory to intravitreal ranibizumab injection [PDF]

, 2014
Ayaka Fujii,1 Hisanori Imai,1,2 Michiko Kanai,1 Atsushi Azumi1,2 1Department of Ophthalmology, Kobe Kaisei Hospital, 2Department of Organ Therapeutics, Division of Ophthalmology, Kobe University Graduate School of Medicine, Kobe, Japan Background: The
Azumi A, Kanai M, Fujii, Ayaka, Imai, Hisanori, Imai H, Kanai, Michiko, Fujii A, Azumi, Atsushi   +7 more
core   +1 more source

Antiangiogenic and Antitumor Activities of Aflibercept, a Soluble VEGF Receptor-1 and -2, in a Mouse Model of Hepatocellular Carcinoma

Neoplasia: An International Journal for Oncology Research, 2016
BACKGROUND & AIM: Aflibercept known as ziv-aflibercept in the United States is a soluble decoy receptor of both vascular endothelial growth factor (VEGF) receptor-1 and -2 known to inhibit the binding of VEGF and placental growth factor (PlGF) to VEGF ...
Takuji Torimura, Hideki Iwamoto, Toru Nakamura, Mitsuhiko Abe, Yu Ikezono, Fumitaka Wada, Takahiko Sakaue, Hiroshi Masuda, Osamu Hashimoto, Hironori Koga, Takato Ueno, Hirohisa Yano   +11 more
doaj   +1 more source

Intraocular Inflammation, Safety Events, and Outcomes After Intravitreal Injection of Ranibizumab, Aflibercept, Brolucizumab, Abicipar Pegol, and Faricimab for nAMD

Journal of VitreoRetinal Diseases
Purpose: To compare the rates of intraocular inflammation (IOI) in patients with neovascular age-related macular degeneration (nAMD) after injection of intravitreal (IVT) antivascular endothelial growth factor drugs.
Marta Stevanovic, Nicole Koulisis, Tom Chen, Stavros N. Moysidis, Bruce Burkemper, Brian C. Toy, Narsing A Rao, Dean Eliott, Mark S. Humayun   +8 more
semanticscholar   +1 more source

Real‐world insights on switching aflibercept dosage for enhanced outcomes in age‐related macular degeneration (RISE‐AMD): Safety data

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate real‐world safety experience with aflibercept 8 mg in a large case series of patients with neovascular age‐related macular degeneration (nAMD). Methods Due to a high proportion of patients on short treatment intervals, patients with nAMD at a Danish tertiary retina clinic were systematically switched to aflibercept 8 mg ...
Mary Graciya Karunainathan, Celine Lee, Kaweh Daniel Zohalinejad, Mads Odgaard Mæng, Nanna Würtz Fabrin, Sigurrós Jónsdóttir, Anne Kjærsgaard Hassing, Søren Kveiborg Yde, Charles C. Wykoff, Henrik Vorum, Yousif Subhi, Marie Ørskov, Lasse Jørgensen Cehofski   +12 more
wiley   +1 more source

Real‐world incidence and clinical characteristics of intraocular inflammation following intravitreal faricimab therapy: A safety study

Acta Ophthalmologica, EarlyView.
Abstract Purpose To estimate the real‐world incidence of intraocular inflammation (IOI) following intravitreal faricimab injections at a large, highly specialized tertiary centre. Methods Single‐centre, retrospective cohort study with chart review using an electronic injection database and electronic medical records from November 2023 to August 2024 ...
Miklos Schneider, Leyla Turan, Farah Arif, Jakob Bjerager, Oliver Niels Klefter, Carsten Faber, Yousif Subhi, Javad Nouri Hajari   +7 more
wiley   +1 more source

Aflibercept 8 mg versus Faricimab Treat-and-Extend for Diabetic Macular Edema or Neovascular Age-Related Macular Degeneration: A Bayesian Fixed-Effect Network Meta-analysis of Clinical Trials

Ophthalmology and Therapy
Reducing intravitreal injection frequency while maintaining efficacy is a critical goal in alleviating the burden associated with anti-vascular endothelial growth factor (VEGF) therapy in patients with diabetic macular edema (DME) or neovascular age ...
Scott M. Friedman, Yingxin Xu, Steven Sherman, Andreas Kuznik, A. Mojebi, S. Keeping, Keith Chan, Theodore Leng, Nimesh A. Patel   +8 more
semanticscholar   +1 more source

Impact of delayed appointments on treatment outcomes in neovascular macular degeneration

Acta Ophthalmologica, EarlyView.
Abstract Purpose To evaluate the real‐world visual outcomes of anti‐vascular endothelial growth factor (anti‐VEGF) therapy, the frequency of delayed appointments and the relationship between delays and visual outcomes in patients with neovascular age‐related macular degeneration (nAMD).
Petri Purola, Pekko Hujanen, Hannu Uusitalo, Hannele Uusitalo‐Järvinen   +3 more
wiley   +1 more source